le rôle de l’omalizumab dans le traitement de l’asthme allergique grave
Clicks: 67
ID: 248239
2006
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
19.8
/100
67 views
9 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #132 of 165 articles by views in religions
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 165 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
CONTEXTE : Un nouveau traitement anti-immunoglobuline E (anti-IgE) contre l’asthme, l’omalizumab, a été approuvé au Canada.
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (17 words).
Try re-searching for a better abstract.
| Reference Key |
chapman2006canadianle
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Kenneth R Chapman;André Cartier;Jacques Hébert;R Andrew McIvor;R Robert Schellenberg |
| Journal | religions |
| Year | 2006 |
| DOI |
10.1155/2006/715173
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.